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Open access under CC A fragment library was screened against the G protein-coupled histamine H4 receptor (H4R) and the
ligand-gated ion channel serotonin 5-HT3A (5-HT3AR). Interestingly, signiﬁcant overlap was found
between H4R and 5-HT3AR hit sets. The data indicates that dual active H4R and 5 HT3AR fragments have
a higher complexity than the selective compounds which has important implications for chemical
genomics approaches. The results of our fragment-based library screening study illustrate similarities
in ligand recognition between H4R and 5-HT3AR and have important consequences for selectivity proﬁling
in ongoing drug discovery efforts on H4R and 5-HT3AR. The afﬁnity proﬁles of our fragment screening
studies furthermore match the chemical properties of the H4R and 5-HT3AR binding sites and can be used
to deﬁne molecular interaction ﬁngerprints to guide the in silico prediction of protein-ligand interactions
and structure.
 2011 Elsevier Ltd. Open access under CC BY license.Fragment-based lead discovery (FBLD) uses low molecular
weight compounds as starting points for hit and lead optimization.
Compared to the drug-like compounds that are screened in typical
high-throughput screening campaigns, fragments are better able to
cover the corresponding chemical space. Consequently, typical
fragment libraries consist of about 1000 small molecules.1 Bio-
chemical and biophysical techniques are used to detect the low
afﬁnity fragment binding. Ligand efﬁciency (LE), deﬁned as the
binding energy of the ligand (DG in kcal mol1) per non-H atom
(Heavy Atoms, HA), is used to select the most promising hits and
guide the optimization studies.2 Typical hit rates for a fragment li-
brary screen are considerably higher than for the high throughput
screening of drug-like compounds.3 The higher complexity of the
latter compounds drastically reduces the chances of perfect com-
plementarity with the biological targets. Thus, fragments are par-
ticularly suited to probe the binding site of receptors,4,5 and are
therefore ideal tools in chemogenomic approaches that link chem-
ical with biological space.6 In chemogenomics studies the effect oficinal Chemistry, Faculty of
De Boelelaan 1083, 1081 HV
ax: +31 205987610.
BY license.a wide array of chemicals on a wide array of biological targets is
investigated.7 The resulting two-dimensional matrix of targets ver-
sus hit compounds is useful for the discovery of ligands for novel
drug targets and to have better control over the selectivity of li-
gands and/or drugs. Furthermore, the data can lead to a better
understanding of ligand-receptor interactions.
We have screened our fragment library against the histamine
H4 receptor (H4R) for which we have ongoing drug discovery pro-
grams. H4R fragment hits were grown into potent H4R ligands and
fragment-merging approaches resulted in efﬁcient scaffold hop-
ping towards new chemical series.8,9 The H4R is considered a very
promising target for treating inﬂammatory and allergic disorders
as well in the modulation of pain and pruritis.10
Meanwhile, the same fragment library is being screened against
a rapidly expanding variety of targets. Here, we describe a remark-
able overlap of the fragment hit set of the H4R and the 5-HT3AR.
This ligand-gated ion channel is a drug target for the treatment
of irritable bowel syndrome (IBS) and chemotherapy-induced nau-
sea and vomiting (CINV).11 Marketed drugs of 5-HT3AR include
tropisteron (Navoban) and palonosetron (Aloxi). The results of
our fragment-based library screening indicate similarities in ligand
recognition between H4R and 5-HT3AR and potential selectivity is-
sues when developing H4R or 5-HT3AR drugs. On the other side,
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to the established role of 5HT3AR in IBS, recent ﬁndings also sug-
gest a role of H4R in this disease. It has been found that an in-
creased innate immune activity in the intestinal mucosa and in
blood is found in subpopulations of patients with IBS.12 Mast cells
and monocytes seem to be particularly important and might indi-
cate that the H4R is also involved in this ailment.
We screened the biological activity of a diverse set of 1010 frag-
ment-like molecules against H4R and 5-HT3AR. The compounds in
this library obey general fragment library rules13: (i) heavy atoms
count 6 22; (ii) clogP <3; (iii) number of H-bond donors 6 3; (iv)
number of H-bond acceptors 6 3; (v) number of rotatable
bonds 6 5. The fragments furthermore contain at least one ring
structure and do not contain reactive functional groups.14 The struc-
tural diversity of the library was analysed, among others, by means
of a scaffold classiﬁcation analysis (SCA).15 In this analysis, frag-
ments are indexedby twoparameters, that is, cyclicity and complex-
ity. Cyclicity is the ratio between ring atoms and side chain atoms
(thus, if all the atoms of the molecule belong to the ring structure
cyclicity equals one). In addition, the complexity was calculated as
a descriptor of the size and shape of the scaffold, taking into account
the smallest set of smallest rings, the number of heavy atoms, the
number of bonds between the heavy atoms, and the sum of heavy
atoms atomic number.15 Chemical diversity of the fragment library
is furthermore conﬁrmed by the fact that only 1.6% of the pair wise
comparisons of the ECFP-4 topological ﬁngerprints of the fragments
give Tanimoto similarity values higher than 0.26.16
For the H4R fragment screen a radioligand displacement study
was performed at a 10 lM fragment concentration. Hits were as-
signed when the fragment displaced 50% or more of the radioli-
gand, resulting in 56 hits (hit rate: 6%). Radioligand binding was
measured by displacement of [3H]histamine using membranes of
HEK293 cells transiently expressing the human H4R.17 For the hit
compounds, afﬁnities were determined by subsequent radioligand
displacement studies.
For the 5-HT3AR we performed a high throughput functional
fragment screen18 using a ﬂuorescent readout (Flex Station) apply-
ing a ﬂuorescent membrane potential dye. With this screening
technique we can identify compounds that have afﬁnity for the
receptor and in addition classify the hits as agonists, antagonists
or inactive. From this fragment screening we identiﬁed 70 hits
for the 5-HT3A receptor (hit rate: 7%). Fragments were screened0.4
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Figure 1. (a) SCA plot showing the hit distribution for the H4R (Red), the 5-HT3AR (blue),
or 5HT3AR (grey). Hits presented in Table 1 are labeled by their corresponding number.
Distribution of the complexity of H4R selective fragments (red line), 5-HT3AR selective fr
grey line).at a concentration of 100 lM using stably expressed human
5-HT3AR in HEK293 cells. Binding afﬁnities of hits were determined
using radioligand binding studies measuring [3H]granisetron
binding using membranes of HEK293 cells expressing the human
5-HT3AR.18
The SCA plot15 in Figure 1a shows the distribution of 5-HT3AR
selective hits, H4R selective hits, and dual 5-HT3AR/H4R hits in the
chemical space covered by the fragment library and demonstrates
the structural diversity of the fragment hits. Interestingly, signiﬁ-
cant overlap between the H4R and 5-HT3AR hit sets occur, for exam-
ple, 24%of the5-HT3ARhits alsobindH4Rand30%of theH4Rhits also
bind 5-HT3AR (Fig. 1b). This is ca. 10% higher than any other overlap
between non-related targets thatwe have screened so far. In Table 1
some selective H4R ligands, selective 5-HT3AR ligands as well as
compounds with afﬁnity for both receptors are displayed. Dual hits
7,8,11have comparable afﬁnities for 5-HT3R andH4R,while dual hit
9 has 500-fold selectivity for 5-HT3R over H4R, and hit 10 has 200-
fold for H4R over 5-HT3R (Table 1).
Many of the dual H4R/5-HT3AR ligands contain a quinazoline,
quinoxaline, aminopyrimidine, imidazole, or benzimidazole scaf-
fold in combination with a positively ionizable ring system
(Table 1). Figure 1c shows that most of these dual H4R/5-HT3AR
fragments have a higher complexity than the H4R and 5-HT3AR
selective fragments. The structural complexity of 71% of the dual
5-HT3A/H4R fragments is 0.7 or higher, while 79% of the H4R selec-
tive hits and 74% of the 5-HT3AR selective fragments is lower than
0.7. While earlier chemoinformatics analyses suggested that
selective ligands are more complex in terms of pharmacophore fea-
tures4 and molecular shape19, our fragment-based chemogenomics
study suggests a more delicate balance between ligand complexity
and target selectivity. Our fragment library screening data indicate
that fragments need to have high enough complexity to hit several
targets, but low enough complexity to be too speciﬁc for a single
site. This is in line with the theoretical model by Hann and
co-workers4 that describes probability of ﬁnding a hit when con-
sidering the complexity of the ligand. The probability of detecting
a binding event is given by multiplying the probability of matching
features and the probability of being able to detect low afﬁnity
binders. Our experimental data set shows that indeed the chance
of ﬁnding fragment hits on two different targets favors higher
complexity compounds. The relatively high complexity of the
overlapping H4R and 5-HT3AR fragment hit set is furthermore a0.8 0.9
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Figure 2. Chemical similarity (ECFP-4 Tc) between dual and selective hits of H4R
and 5-HT3AR and the endogenous ligands of H4R (histamine) and 5-HT3AR
(serotonin).
Table 1
Structures of fragments that bind solely H4R (1–3), solely 5-HT3AR (4–6) and both
H4R and 5-HT3AR (7–11)
# H4R/5-HT3AR Structure Afﬁnity (pKi)
H4Ra 5-HT3ARc
1
NH
NN
7.0 ± 0.1 n.a.
2 N
H
N
NH
6.2 ± 0.1 n.a.
3
N
N
NN
6.7 ± 0.0 n.a.
4
HN
Cl
n.a. 6.1 ± 0.2
5
N NH2
n.a. 6.0 ± 0.0
6 N
H
NH2
NH n.a. 6.1 ± 0.1
7
Cl
N N
N
6.2 ± 0.0 6.6 ± 0.3
8
ON
H
N N
N
7.2 ± 0.0 7.9 ± 0.3
9 Cl N
N
H
N
6.1 ± 0.1b 8.8 ± 0.1
10
N
N
NN
NH2
8.2 ± 0.1 5.9 ± 0.1
11
NH
N
6.2 ± 0.1b 5.9 ± 0.3
n.a.: Non active.
a Measured by displacement of [3H]histamine binding using membranes of
HEK293 cells transiently expressing the human H4R. pKi’s are calculated from at
least three independent measurements as the mean ± SEM.
b Determined using membranes of SK-N-MC cells transiently expressing the
human H4R. pKi’s are calculated from at least three independent measurements as
the mean ± SEM.
c pKi: Measured by displacement of [3H]granisetron binding using membranes of
HEK293 cells expressing the human 5-HT3AR. pKi’s are calculated from at least two
independent measurements as the mean ± SEM.
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tors are similar. Figure 2 shows the chemical similarity of the frag-
ment library compared to serotonin and histamine (determined by
Pipeline Pilot ECFP-4 circular ﬁngerprint20 Tanimoto similarity
coefﬁcients (Tc)). While some of the H4R selective fragments
(38%) are chemically similar to histamine (i.e., ECFP-4 Tc >0.26
including 2 (Table 1)), none of the 5-HT3AR selective fragments
share chemical similarity serotonin-like, and only two of the dualbinders are histamine-like (including 11 see Table 1). These data
show that complex H4R/5-HT3AR dual fragments are dissimilar
from the (less complex) endogenous ligands of H4R and 5-HT3AR.
The higher complexity of the dual H4R and 5-HT3AR fragments is
further illustrated by the analysis of the physical-chemical distri-
butions of fragment hits (Fig. 3). Whereas most properties are sim-
ilar when comparing the selective and the dual activity fragments
(see Table S1, S2 and Figure S1 for details21), the number of rings
and the heavy atom count (and associated molecular weight) are
higher for the dual activity hits compared to for H4R and 5-HT3AR
selective fragments (Fig. 3 and Table S2).
The fragment screening does not only illustrate similarities in
H4R and 5-HT3AR binding proﬁles, but also identiﬁes subtle differ-
ences between the properties of selective receptor ligands. Figure 3
shows that the number of H-bond donor atoms is signiﬁcantly high-
er for the H4R selective fragments (on average 1.7 H-bond donors)
than for 5-HT3AR selective fragments (on average 0.8 H-bond
donors). This can be correlated with the H4R ligand pharmaco-
phore22 that contains twoH-bonddonors. In theH4Rbindingpocket,
these features are complementary to two negatively charged
residues, D3.32 and E5.46 (Fig. 4).22 As a result of these strong
non-hydrophobic interactions23 between ionizable H-bonding
partners, many H4R ligands (including the high afﬁnity endogenous
ligand histamine) can bind the receptor with a high lipophilic
efﬁciency,24 explaining the relatively low c log P valuesofH4R ligand
(Fig. 3). In the 5-HT3AR binding pocket one essential glutamate
H-bond interaction partner (E129) has been identiﬁed (Fig. 4).25
Ligand binding to 5-HT3AR is furthermore largely determined by
aromatic interactions like p–p stacking and cation-p interactions
(W183, W195, Y141, Y143, Y153, Y234, see Fig. 4)25,26, matching
the requirement of a lower number of H-bond donors (and
somewhat higher hydrophobicity) for 5-HT3AR ligands compared
to H4R ligands. In line with the notion that the H4R binding site
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Figure 3. Distribution of physical-chemical properties that discriminate H4R selective fragments (red), 5-HT3AR selective fragments (blue line), dual H4R/5-HT3AR fragments
(green), and inactives (grey dotted line). Distributions of other physical-chemical properties do not discriminate between the sets as shown in Figure S1
a H4R 5-HT3AR
E129
Y234
W183 HOH1
HOH2
Y153
F7.39
Y6.51
Y3.33
E5.46
C3.36
D3.32
H4R
5-HT3AR
1) contact; 2) face-to-face stacking; 3) edge-to-face stacking; 4) HB acc.-HB don.; 5) HB don.-HB acc.; 6) neg.-pos.; 7) pos.-neg. (extra: 8) cation-pi) 
b
Figure 4. Panel A shows the predicted binding modes of the dual H4R/5-HT3AR hit 8 (green carbon atoms, see Table 1 for molecular structure) in structural models of H4R and
5-HT3AR. Parts of the backbone of transmembrane (TM) helices 3, 5, 6 and 7 (the top TM3 is not shown for clarity) in H4R and loops A, B, C and E of the extracellular ligand-
binding domain (ECD) of 5-HT3AR are represented by light yellow ribbons. Important binding residues are depicted as ball-and-sticks with grey carbon atoms. Oxygen,
nitrogen, and hydrogen atoms are colored red, blue, and cyan, respectively. H-bonds described in the text are depicted by black dots. The molecular interaction ﬁngerprint
(IFP)27 bit strings of 8 in H4R and 5-HT3AR are compared in panel B.
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H4R: pKi: 7.1
5-HT3AR: 98% inh. at 10µM
13
H4R: pKi: 7.1
5-HT3AR: 98% inh. at 10µM
Figure 5. Compounds in preclinical trials by Abbott.
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site only one such atom, is the observation that fragment 10
possesses afﬁnity for both 5-HT3AR and H4R, whereas the
analogous fragment 3 that lacks an NH2 group, only shows afﬁnity
for the H4R.
Figure 4 demonstrates how the afﬁnity proﬁles from our frag-
ment screening studies correspond with the chemical properties
of the H4R and 5-HT3AR binding sites and can be used to derive
molecular interaction ﬁngerprints27 and validate structural models
of protein-ligand complexes.28 In both H4R17 and 5-HT3AR models
(see Supplementary data for a description of the protein modeling
procedure), the positively ionizable piperazine group of the dual
H4R/5-HT3AR hit 8 forms a salt bridge (D3.32 in H4R, E129 in
5-HT3AR) and makes cation-p (F7.39 in H4R, Y234 and W183 in 5-
HT3AR) and aromatic p–p stacking interactions (Y3.33 and Y6.51
in H4R, Y153 in 5-HT3AR). Interestingly, while C3.36 and E5.46 are
proposed to act as H-bond donor and acceptor to the carboxamide
group of 10 in H4R, two water molecules (which form a conservedprotein-ligand H-bond interaction network in several crystal struc-
tures of the homologous AChBP29) fulﬁll the same role in 5-HT3AR.
The binding mode modes of 8 presented in Figure 4 do not only
match the fragment-based chemogenomics analysis reported in
5464 M. H. P. Verheij et al. / Bioorg. Med. Chem. Lett. 21 (2011) 5460–5464the current study, but are also supported by earlier reported site-di-
rectedmutagenesis studies, underlining the important role of E129,
W183, Y153, and Y23425,26 in ligand binding to 5-HT3AR, and the
essential role of D3.32 and E5.46 in H4R-ligand interactions.22–24
The binding orientation of 8 is furthermore in line with previously
experimentally validated ligand binding modes in H4R.17
Chemogenomics analyses of inter-gene family ligand promiscu-
ity is of growing interest.30 Although GPCRs and LGICs obviously
have a very different protein architecture, their ligand-binding
sites can obviously bind similar (sub)structures. In this respect,
the special chemical taxonomy of serotonin, that binds to several
GPCRs and one ion-channel (5-HT3A) has been previously noted.31
Moreover, Mestres and co-workers have recently reported a strik-
ing cross-pharmacology between aminergic GPCRs and the 5-HT3
receptors in their in silico target proﬁling platform.32 Our fragment
screening studies complement these ﬁndings by identifying rela-
tively high fragment cross-reactivity between H4R and 5-HT3AR
( Fig. 1b) and demonstrate that fragments are ideally suited to
interrogate ligand binding sites. In the hit optimization phase,
selectivity for either H4R or 5-HT3AR can be achieved, although in
some cases this might proof complicated. This is illustrated by re-
cent publications from Abbott Laboratories.33,34 These studies, that
are part of their H4R drug development program, describe the
in vitro and in vivo characterization of the H4R ligands 12 and 13
(A-940894). Intriguingly, both these compounds ( Fig. 5) show
strong inhibition at the 5-HT3AR receptor (98% inhibition at
10 lM). It is noted that these compounds contain the 2-amino-4-
piperazine-pyrimidine scaffold that was also identiﬁed as binding
to both H4R and 5-HT3AR in our fragment-screening (fragment
10, table 1).
In conclusion, the present study identiﬁes a signiﬁcant overlap
between the hit fragment set for H4R and 5-HT3AR, illustrating sim-
ilarities in ligand recognition and suggests that fragment-based
chemogenomics analysis and molecular modeling building can be
used to efﬁciently navigate chemical space during hit optimization
in programs aimed to develop selective leads or compounds with a
dual activity proﬁle.
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